ACTHar ( DrugBank: - )

---

9 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2
13	Multiple sclerosis/Neuromyelitis optica	12
14	Chronic inflammatory demyelinating polyneuropathy	1
46	Malignant rheumatoid arthritis	7
49	Systemic lupus erythematosus	4
50	Dermatomyositis	3
66	IgA nephropathy	2
84	Sarcoidosis	7
222	Primary nephrotic syndrome	6

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

14. Chronic inflammatory demyelinating polyneuropathy

---

Clinical trials : 175 / Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

49. Systemic lupus erythematosus

---

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

50. Dermatomyositis

---

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

66. IgA nephropathy

---

Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

84. Sarcoidosis

---

Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

222. Primary nephrotic syndrome

---

Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries